Tango Therapeutics, Inc. (TNGX) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
TNGX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TNGX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 96.3% | -178.4% | -162.9% |
| 2024 | 100.0% | -346.1% | -309.7% |
| 2023 | 100.0% | -312.6% | -278.5% |
| 2022 | 100.0% | -446.8% | -435.1% |
| 2021 | 100.0% | -157.1% | -157.2% |
Download Data
Export TNGX earnings history in CSV or JSON format
Free sign-in required to download data
Tango Therapeutics, Inc. (TNGX) Earnings Overview
As of May 8, 2026, Tango Therapeutics, Inc. (TNGX) reported trailing twelve-month net income of -$102M, reflecting +26.9% year-over-year growth. The company earned $-0.87 per diluted share over the past four quarters, with a net profit margin of -162.9%.
Looking at the long-term picture, TNGX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$14M in fiscal 2019.
Tango Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RVMD (-$1.37B net income), KYMR (-$315M net income, -794.4% margin), PRAX (-$327M net income), TNGX has comparable earnings metrics. Compare TNGX vs RVMD →
TNGX Earnings vs Peers
Earnings metrics vs comparable public companies
TNGX Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$102M | +22.0% | -$111M | $-0.87 | -162.9% | -178.4% |
| 2024 | -$130M | -28.1% | -$146M | $-1.19 | -309.7% | -346.1% |
| 2023 | -$102M | +5.9% | -$114M | $-1.08 | -278.5% | -312.6% |
| 2022 | -$108M | -85.8% | -$111M | $-1.23 | -435.1% | -446.8% |
| 2021 | -$58M | -12.1% | -$58M | $-0.94 | -157.2% | -157.1% |
| 2020 | -$52M | -268.7% | -$52M | $-1.62 | -678.8% | -681.8% |
| 2019 | -$14M | - | -$15M | $-1.57 | -57.2% | -61.5% |
See TNGX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TNGX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TNGX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTNGX — Frequently Asked Questions
Quick answers to the most common questions about buying TNGX stock.
Is TNGX growing earnings?
TNGX EPS is $-0.87, with earnings growth accelerating to +26.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-102M.
What are TNGX's profit margins?
Tango Therapeutics, Inc. net margin is -162.9%, with operating margin at -178.4%. Below-average margins reflect competitive or cost pressures.
How consistent are TNGX's earnings?
TNGX earnings data spans 2019-2025. The accelerating earnings trend is +26.9% YoY. Historical data enables comparison across business cycles.